Resumen
La prevalencia del deterioro cognitivo mínimo en pacientes con EP está en un rango de 20-50 %. La prevalen-cia puntual de la demencia asociada a la enfermedad se estima en alrededor del 25-30 °% con un incremento proporcional en relación con la edad y el tiempo de evolución de la enfermedad. El perfil clínico puede ser heterogéneo y hace referencia a la alteración en los diferentes dominios que supone un substrato neurobiológico diferente. La disfunción ejecutiva suele ser más frecuente en etapas tempranas de la enfermedad, aunque también hay perfiles clínicos corticales. Hay síntomas neuropsiquiátricos como la depresión, la ansiedad y el discontrol de impulsos que pueden afectar la cognición. La valoración rutinaria de las actividades de la vida diaria y el desempeño funcional se ha relacionado con el grado de compromiso así como con el rendimiento cognitivo global. Pacientes en estadios avanzados y candidatos a la cirugía de estimulación cerebral profunda requieren la evaluación neuropsicológica para seguimiento e identificación de potenciales riesgos o contraindicaciones cognitivas, comportamentales y/o emocionales. Las conclusiones del consenso de cognición son: 1) el deterioro cognitivo mínimo es común en los pacientes, incluso en estadios tempranos; 2) el perfil clínico es heterogéneo, aunque la disfunción ejecutiva es más frecuente; 3) la valoración inicial permite detectar perfiles de riesgo a demencia; 4) deben usarse instrumentos validados para esta población; 5) los síntomas neuropsiquiátricos pueden afectar el desempeño del paciente, y 6) la valoración de la independencia funcional permite explorar el impacto de la cognición en la cotidianidad.
Citas
Jahanshahi M, Obeso I, Rothwell JC, Obeso JA. A fronto-striato-subthalamic-pallidal network for goal-directed and habitual inhibition. Nat Rev Neurosci. 2015 Dec;16(12):719-32.
Armstrong MJ. Lewy Body Dementias: Contin Lifelong Learn Neurol. 2019 Feb;25(1):128-46.
Biundo R, Weis L, Antonini A. Cognitive decline in Parkinson's disease: the complex picture. Npj Park Dis [Internet]. 2016 Dec [cited 2018 May 21];2(1). Available from: Available from: http://www.nature.com/articles/npjparkd201618
Goldman JG, Litvan I. Mild cognitive impairment in Parkinson's disease. Minerva Med. 2011 Dec;102(6):441-59.
GBD 2016 Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019 Mar 14;
Winter Y, von Campenhausen S, Arend M, Longo K, Boetzel K, Eggert K, et al. Health-related quality of life and its determinants in Parkinson's disease: results of an Italian cohort study. Parkinsonism Relat Disord. 2011 May;17(4):265-9.
Bocanegra Y, Trujillo-Orrego N, Pineda D. [Dementia and mild cognitive impairment in Parkinson's disease: a review]. Rev Neurol. 2014 Dec 16;59(12):555-69.
Muslimovic D, Post B, Speelman JD, Schmand B. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology. 2005 Oct 25;65(8):1239-45.
Kehagia AA, Barker RA, Robbins TW. Cognitive Impairment in Parkinson s Disease: The Dual Syndrome Hypothesis. Neurodegener Dis. 2013;11:79-92.
Gratwicke J, Jahanshahi M, Foltynie T. Parkinson's disease dementia: a neural networks perspective. Brain. 2015 Jun;138(6):1454-76.
van Rooden SM, Colas F, Martínez-Martín P, Visser M, Verbaan D, Marinus J, et al. Clinical subtypes of Parkinson's disease. Mov Disord. 2011 Jan;26(1):51-8.
Marras C, Lang A. Parkinson's disease subtypes: lost in translation? J Neurol Neurosurg Psychiatry. 2013 Apr 1;84(4):409-15.
Burn DJ. Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2006 May 1;77(5):585-9.
Amboni M, Barone P, Iuppariello L, Lista I, Tranfaglia R, Fasano A, et al. Gait patterns in parkinsonian patients with or without mild cognitive impairment. Mov Disord. 2012 Oct;27(12):1536-43.
Goldman JG, Weis H, Stebbins G, Bernard B, Goetz CG. Clinical differences among mild cognitive impairment subtypes in Parkinson's disease. Mov Disord. 2012 Aug;27(9):1129-36.
Williams-Gray CH, Evans JR, Goris A, Foltynie T, Ban M, Robbins TW, et al. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain. 2009 Nov;132(11):2958-69.
Aarsland D, Creese B, Politis M, Chaudhuri KR, ffytche DH, Weintraub D, et al. Cognitive decline in Parkinson disease. Nat Rev Neurol. 2017 Apr;13(4):217-31.
Hiorth YH, Lode K, Larsen JP. Frequencies of falls and associated features at different stages of Parkinson's disease. Eur J Neurol. 2013 Jan;20(1):160-6.
Sollinger AB, Goldstein FC, Lah JJ, Levey AI, Factor SA. Mild cognitive impairment in Parkinson's disease: Subtypes and motor characteristics. Parkinsonism Relat Disord. 2010 Mar;16(3):177-80.
Yogev G, Giladi N, Peretz C, Springer S, Simon ES, Hausdorff JM. Dual tasking, gait rhythmicity, and Parkinson's disease: Which aspects of gait are attention demanding? Eur J Neurosci. 2005 Sep;22(5):1248-56.
O'Callaghan C, Lewis SJG. Cognition in Parkinson's Disease. In: International Review of Neurobiology [Internet]. Elsevier; 2017 [cited 2018 Jun 22]. p. 557-83. Available from: Available from: http://linkinghub.elsevier.com/retrieve/pii/S0074774217300466
Schulz J, Pagano G, Fernández Bonfante JA, Wilson H, Politis M. Nucleus basalis of Meynert degeneration precedes and predicts cognitive impairment in Parkinson's disease. Brain. 2018 May 1;141(5):1501-16.
Richardson K, Fox C, Maidment I, Steel N, Loke YK, Arthur A, et al. Anticholinergic drugs and risk of dementia: case-control study. BMJ. 2018 Apr 25;361:k1315.
Skorvanek M, Goldman JG, Jahanshahi M, Marras C, Rektorova I, Schmand B, et al. Global scales for cognitive screening in Parkinson's disease: Critique and recommendations. Mov Disord Off J Mov Disord Soc. 2018;33(2):208-18.
Factor SA, Bennett A, Hohler AD, Wang D, Miyasaki JM. Quality improvement in neurology: Parkinson disease update quality measurement set: Executive summary. Neurology. 2016 14;86(24):2278-83.
Goldman JG, Vernaleo BA, Camicioli R, Dahodwala N, Dobkin RD, Ellis T, et al. Cognitive impairment in Parkinson's disease: a report from a multidisciplinary symposium on unmet needs and future directions to maintain cognitive health. Npj Park Dis [Internet]. 2018 Dec [cited 2019 Apr 1];4(1). Available from: Available from: http://www.nature.com/articles/s41531-018-0055-3
Litvan I, Aarsland D, Adler CH, Goldman JG, Kulisevsky J, Mollenhauer B, et al. MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Mov Disord Off J Mov Disord Soc. 2011 Aug 15;26(10):1814-24.
Estrada-Orozco K, Bonilla-Vargas K, Cruz F, Mancera O, Ruiz M, Alvarez L, et al. Cognitive Assessment Test: Validation of a Short Cognitive Test for the Detection of Mild Cognitive Disorder. Int J Alzheimers Dis. 2018;2018:3280621.
Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005 Apr;53(4):695-9.
Rossetti HC, Lacritz LH, Cullum CM, Weiner MF. Normative data for the Montreal Cognitive Assessment (MoCA) in a population-based sample. Neurology. 2011 Sep 27;77(13):1272-5.
Pedraza OL, Salazar AM, Sierra FA, Soler D, Castro J, Castillo P, et al. Confiabilidad, validez de criterio y discriminante del Montreal Cognitive Assessment (MoCA) test, en un grupo de adultos de Bogotá. 41(4):221-8.
Gill DJ, Freshman A, Blender JA, Ravina B. The Montreal cognitive assessment as a screening tool for cognitive impairment in Parkinson's disease. Mov Disord Off J Mov Disord Soc. 2008 May 15;23(7):1043-6.
Nazem S, Siderowf AD, Duda JE, Have TT, Colcher A, Horn SS, et al. Montreal cognitive assessment performance in patients with Parkinson's disease with "normal" global cognition according to mini-mental state examination score. J Am Geriatr Soc. 2009 Feb;57(2):304-8.
Lessig S, Nie D, Xu R, Corey-Bloom J. Changes on brief cognitive instruments over time in Parkinson's disease. Mov Disord Off J Mov Disord Soc. 2012 Aug;27(9):1125-8.
Dalrymple-Alford JC, MacAskill MR, Nakas CT, Livingston L, Graham C, Crucian GP, et al. The MoCA: well-suited screen for cognitive impairment in Parkinson disease. Neurology. 2010 Nov 9;75(19):1717-25.
Hoops S, Nazem S, Siderowf AD, Duda JE, Xie SX, Stern MB, et al. Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology. 2009 Nov 24;73(21):1738-45.
Chou KL, Lenhart A, Koeppe RA, Bohnen NI. Abnormal MoCA and normal range MMSE scores in Parkinson disease without dementia: cognitive and neurochemical correlates. Parkinsonism Relat Disord. 2014 Oct;20(10):1076-80.
Marinus J, Visser M, Verwey NA, Verhey FRJ, Middelkoop H A. M, Stiggelbout AM, et al. Assessment of cognition in Parkinson's disease. Neurology. 2003 Nov 11;61(9):1222-8.
Kulisevsky J, Pagonabarraga J. Cognitive impairment in Parkinson's disease: tools for diagnosis and assessment. Mov Disord Off J Mov Disord Soc. 2009 Jun 15;24(8):1103-10.
Matteau E, Dupré N, Langlois M, Provencher P, Simard M. Clinical validity of the Mattis Dementia Rating Scale-2 in Parkinson disease with MCI and dementia. J Geriatr Psychiatry Neurol. 2012 Jun;25(2):100-6.
Hobson P, Meara J. Mild cognitive impairment in Parkinson's disease and its progression onto dementia: a 16-year outcome evaluation of the Denbighshire cohort: Mild cognitive impairment in Parkinson's disease. Int J Geriatr Psychiatry. 2015 Oct;30(10):1048-55.
Domellöf ME, Elgh E, Forsgren L. The relation between cognition and motor dysfunction in drug-naive newly diagnosed patients with Parkinson's disease. Mov Disord Off J Mov Disord Soc. 2011 Oct;26(12):2183-9.
Aarsland D, Muniz G, Matthews F. Nonlinear decline of minimental state examination in Parkinson's disease. Mov Disord. 2011 Feb 1;26(2):334-7.
Litvan I, Goldman JG, Tröster AI, Schmand BA, Weintraub D, Petersen RC, et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord. 2012 Mar;27(3):349-56.
Tröster AI, Woods SP, Morgan EE. Assessing cognitive change in Parkinson's disease: development of practice effect-corrected reliable change indices. Arch Clin Neuropsychol Off J Natl Acad Neuropsychol. 2007 Aug;22(6):711-8.
Foltynie T, Brayne CEG, Robbins TW, Barker RA. The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. Brain J Neurol. 2004 Mar;127(Pt 3):550-60.
Tröster AI. Some Clinically Useful Information that Neuro-psychology Provides Patients, Carepartners, Neurologists, and Neurosurgeons About Deep Brain Stimulation for Parkinson's Disease. Arch Clin Neuropsychol Off J Natl Acad Neuropsychol. 2017 Nov 1;32(7):810-28.
Combs HL, Folley BS, Berry DTR, Segerstrom SC, Han DY, Anderson-Mooney AJ, et al. Cognition and Depression Following Deep Brain Stimulation of the Subthalamic Nucleus and Globus Pallidus Pars Internus in Parkinson's Disease: A Meta-Analysis. Neuropsychol Rev. 2015 Dec;25(4):439-54.
Martínez-Martínez AM, Aguilar OM, Acevedo-Triana CA. Meta-Analysis of the Relationship between Deep Brain Stimulation in Patients with Parkinson's Disease and Performance in Evaluation Tests for Executive Brain Functions. Park Dis. 2017;2017:9641392.
Lezak MD, editor. Neuropsychological assessment. 5th ed. Oxford ; New York: Oxford University Press; 2012. 1161 p.
Arango Lasprilla JC, Rivera D, editors. Neuropsicología en Colombia: datos normativos, estado actual y retos a futuro. Manizales, Colombia: UAM, Universidad Autónoma de Manizales; 2015. 287 p. (Colección Ciencias de la salud. Investigación).
Agrell B, Dehlin O. The clock-drawing test. Age Ageing. 2012 Nov 1;41(suppl 3):iii41-5.
Starkstein SE, Mayberg HS, Preziosi TJ, Andrezejewski P, Leiguarda R, Robinson RG. Reliability, validity, and clinical correlates of apathy in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 1992;4(2):134-9.
Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994 Dec;44(12):2308-14.
Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol. 2006 Mar;5(3):235-45.
Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci. 2017 Jul;18(7):435-50.
Weintraub D, Hoops S, Shea JA, Lyons KE, Pahwa R, Driver-Dunckley ED, et al. Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease. Mov Disord. 2009 Jul 30;24(10):1461-7.
Vilalta Franch J, Lozano Gallego M, Hernández Ferràndiz M, Llinàs Reglà J, López Pousa S, López OL. Neuropsychiatric inventory. Propiedades psicométricas de su adaptación al español. Rev Neurol. 1999;29(01):15.
Chaudhuri KR, Martinez-Martin P, Schapira AHV, Stocchi F, Sethi K, Odin P, et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. Mov Disord Off J Mov Disord Soc. 2006 Jul;21(7):916-23.
Martinez-Martin P, Rodriguez-Blazquez C, Abe K, Bhat-tacharyya KB, Bloem BR, Carod-Artal FJ, et al. International study on the psychometric attributes of the Non-Motor Symptoms Scale in Parkinson disease. Neurology. 2009 Nov 10;73(19):1584-91.
Bangen KJ, Jak AJ, Schiehser DM, Delano-Wood L, Tuminello E, Han SD, et al. Complex activities of daily living vary by mild cognitive impairment subtype. J Int Neuropsychol Soc JINS. 2010 Jul;16(4):630-9.
Kulisevsky J, Fernández de Bobadilla R, Pagonabarraga J, Martínez-Horta S, Campolongo A, García-Sánchez C, et al. Measuring functional impact of cognitive impairment: validation of the Parkinson's disease cognitive functional rating scale. Parkinsonism Relat Disord. 2013 Sep;19(9):812-7.
Martinez-Martin P, Rodriguez-Blazquez C, Forjaz MJ, Kurtis MM, Skorvanek M. Measurement of Nonmotor Symptoms in Clinical Practice. Int Rev Neurobiol. 2017;133:291-345.
Seppi K, Ray Chaudhuri K, Coelho M, Fox SH, Katzen-schlager R, Perez Lloret S, et al. Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review. Mov Disord Off J Mov Disord Soc. 2019 Feb;34(2):180-98.
Henderson EJ, Lord SR, Brodie MA, Gaunt DM, Lawrence AD, Close JCT, et al. Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2016 Mar;15(3):249-58.
Emre M, Tsolaki M, Bonuccelli U, Destée A, Tolosa E, Kutzelnigg A, et al. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010 Oct;9(10):969-77.
Wang H-F, Yu J-T, Tang S-W, Jiang T, Tan C-C, Meng X-F, et al. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review "with meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry. 2015 Feb;86(2):135-43.
Nikolin S, Huggins C, Martin D, Alonzo A, Loo CK. Safety of repeated sessions of transcranial direct current stimulation: A systematic review. Brain Stimulat. 2018 Apr;11(2):278-88.
Wagle Shukla A, Shuster JJ, Chung JW, Vaillancourt DE, Patten C, Ostrem J, et al. Repetitive Transcranial Magnetic Stimulation (rTMS) Therapy in Parkinson Disease: A Meta-Analysis. PM R. 2016 Apr;8(4):356-66.
Kalbe E, Aarsland D, Folkerts A-K. Cognitive Interventions in Parkinson's Disease: Where We Want to Go within 20 Years. J Park Dis. 2018;8(s1):S107-13.
Biundo R, Weis L, Fiorenzato E, Antonini A. Cognitive Rehabilitation in Parkinson's Disease: Is it Feasible? Arch Clin Neuropsychol. 2017 Nov 1;32(7):840-60.
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.